Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Washington Court Hotel

25 sep 2013 8:00 a.m. - 27 sep 2013 5:00 p.m.

525 New Jersey Avenue NW, Washington, DC 20001

DIA/FDA Oligonucleotide-based Therapeutics Conference

Session Chair(s)

Doug  Kornbrust, PHD

Doug Kornbrust, PHD

President

Preclinsight, United States

Shwu-Luan  Lee, PHD

Shwu-Luan Lee, PHD

Pharmacologist, Office of New Drug, CDER

FDA, United States

Speaker(s)

Tacey E. White, PHD

Considerations in Assessment of Reproductive and Developmental Risk for Oligonucleotide-based Therapies

Tacey E. White, PHD

Aclairo, Inc, United States

Senior Consultant

Cindy L. Berman, PHD

Final Recommendations of the OSWG Genetox Subcommittee: Standard Battery and Beyond

Cindy L. Berman, PHD

Berman Consulting, United States

Independent Consultant

Morten  Lindow, PHD

Measurement and Prediction of Hybridization-induced Off-target Effects of Oligonucleotide Drug Candidates

Morten Lindow, PHD

Santaris Pharma A/S, Denmark

Group Leader, Integrative Systems Biology

David H. Schubert

Panelist

David H. Schubert

United States

Jennifer  Marlowe, PHD

Panelist

Jennifer Marlowe, PHD

bluebirdbio, United States

Senior Director, Preclinical Development

Arthur A. Levin, PHD

Panelist

Arthur A. Levin, PHD

Avidity Biosciences, United States

Distinguished Scientist

Scott  Henry, PHD

Panelist

Scott Henry, PHD

Ionis Pharmaceuticals, Inc., United States

Senior Vice President, Nonclinical Development

Rosanne  Seguin, PHD

Panelist

Rosanne Seguin, PHD

McGill University, Canada

Cindy L. Berman, PHD

Panelist

Cindy L. Berman, PHD

Berman Consulting, United States

Independent Consultant

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.